` Comparison: BT3 vs PNEXF - Alpha Spread

L
BT3
vs
PNEXF

Over the past 12 months, BT3 has significantly outperformed PNEXF, delivering a return of +123% compared to the PNEXF's 0% growth.

Start AI Comparison

Smart Verdict
AI-Powered

Not Sure Which Stock Wins?
Let AI Decide.
BT3
PNEXF
One-click summary across all key metrics.
Ranked results with clear takeaways.
No spreadsheets, no guesswork.
One-click summary across all key metrics.
Ranked results with clear takeaways.
No spreadsheets, no guesswork.
Start AI Comparison
Smart Verdict is Ready!
See Who Stands Out.
All the numbers, charts, and metrics summarized into one smart verdict.
Stocks Compared:
Show Comparison Results
Summarizing...
We need a little more time to summarize the results

Valuation Comparison

BT3 Intrinsic Value
HIDDEN
Show
PNEXF Intrinsic Value
HIDDEN
Show
Company Last Price Intrinsic Value DCF Value Relative Value Wall St Target
L
Lineage Cell Therapeutics Inc
F:BT3
1.44 EUR
Pharnext SCA
OTC:PNEXF
999 999.9999 USD
No Stocks Selected

Compare the stock's valuation with its competitors.

Select Stocks to Compare
Valuation Scenario:
Bear Case
Base Case
Bull Case

Growth Comparison

Growth Over Time
BT3, PNEXF

BT3
PNEXF
Add Stock
Revenue
www.alphaspread.com
No Stocks Selected

Compare company's financials with its competitors.

Select Stocks to Compare
Company LTM Historical Growth Growth Streak % Positive Years Max Drawdown Volatility Forecasted Growth
3 Years 5 Years 10 Years 1 Year 3 Years
L
Lineage Cell Therapeutics Inc
Revenue
Pharnext SCA
Revenue

All metrics are calculated based on data from the last 10 years.

No Stocks Selected

Compare company's financials with its competitors.

Select Stocks to Compare

Profitability Comparison

Free Cash Flow
BT3, PNEXF

BT3
PNEXF
Add Stock
Free Cash Flow
www.alphaspread.com
No Stocks Selected

Compare company's free cash flow with its competitors.

Select Stocks to Compare
Company LTM Average Historical Growth FCF Margin Conversion
3 Years 5 Years 3 Years 5 Years 10 Years
L
Lineage Cell Therapeutics Inc
F:BT3
Pharnext SCA
OTC:PNEXF
No Stocks Selected

Compare company's free cash flow with its competitors.

Select Stocks to Compare
What is Free Cash Flow?

Gross Margin

BT3
97.6%
PNEXF
0%

Operating Margin

BT3
-186.9%
PNEXF
-17 526.7%

Net Margin

BT3
-374.8%
PNEXF
-21 040%

FCF Margin

BT3
-212.1%
PNEXF
-15 953.3%

ROE

BT3
-70.1%
PNEXF
114.6%

ROA

BT3
-42.3%
PNEXF
-391.1%

ROIC

BT3
-37.4%
PNEXF
3 092.9%

ROCE

BT3
-24.3%
PNEXF
275.4%

Solvency Comparison

No Stocks Selected

Compare company's equity waterfall with its competitors.

Select Stocks to Compare
Balance Sheet Comparison
No Stocks Selected

Compare company's balance sheet with its competitors.

Select Stocks to Compare

Stocks Performance

Stocks Performance
BT3, PNEXF

Loading
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
BT3, PNEXF

Performance Gap Between BT3 and PNEXF
HIDDEN
Show

Performance By Year
BT3, PNEXF

Loading
BT3
PNEXF
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
Not Sure Which Stock Wins?
Let AI Decide
One-click summary across all key metrics.
Ranked results with clear takeaways.
No spreadsheets, no guesswork.
Start AI Comparison
Compare BT3 to other stocks
Custom
Choose any stock to compare
Unlock Full Access to Alpha Spread
Create Free Account